Question 1

What is Ocrelizumab?

Accepted Answer

Ocrelizumab is a laboratory-made monoclonal antibody designed to target specific proteins in the immune system. It works by binding to CD20, a protein found on the surface of certain types of B cells that play a role in the body's immune response.

By reducing these specific cells, the medication helps to limit immune activity against the central nervous system. This process is intended to help treat multiple sclerosis and manage its progression.

Question 2

What is Ocrelizumab used for?

Accepted Answer

Ocrelizumab is used to treat multiple sclerosis .

Question 3

How does Ocrelizumab work?

Accepted Answer

Mechanism of Action

Ocrelizumab is a humanized monoclonal antibody. It is designed to target and bind to a specific protein called CD20, which is found on the surface of B cells, a type of white blood cell in the immune system.

In multiple sclerosis (MS), the immune system mistakenly attacks the protective coating (myelin) that surrounds nerves in the brain and spinal cord. B cells are believed to play a significant role in this immune response and the resulting nerve damage. By binding to the CD20 protein, ocrelizumab causes these specific B cells to be depleted or removed from the body.

By reducing the number of these B cells, the medication helps to:

Reduce inflammation: Lowering the immune system's activity in the central nervous system.

Prevent nerve damage: Limiting the attacks on the myelin sheath that covers nerve fibers.

Slow disease progression: Decreasing the frequency of relapses and the worsening of physical disability.

While the exact way ocrelizumab works to treat MS is not fully understood, its primary effect is the targeted reduction of B cells involved in the disease process.

Question 4

What are the brand names for Ocrelizumab?

Accepted Answer

Ocrelizumab is sold under the brand name Ocrevus .

Question 5

What are the active ingredients in Ocrelizumab?

Accepted Answer

The active ingredient in Ocrelizumab is ocrelizumab .

Question 6

What are the side effects of Ocrelizumab?

Accepted Answer

Common side effects of Ocrelizumab may include:

Infusion reactions

Upper respiratory infection

Fatigue

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Ocrelizumab?

Accepted Answer

Ocrelizumab belongs to the anti-CD20 monoclonal antibody drug class.

Question 8

What is the dosage of Ocrelizumab and how do I take it?

Accepted Answer

Administration Method

Ocrelizumab is given as an infusion into a vein (intravenously) by a healthcare provider in a hospital or clinical setting. The infusion process usually takes several hours to complete.

Dosing Schedule

The treatment usually begins with two separate infusions given two weeks apart. After these initial doses, the medication is typically administered as a single infusion once every six months.

Before and During the Infusion

To help prevent or reduce the severity of infusion-related reactions, your healthcare provider may give you other medications, such as a corticosteroid or an antihistamine, shortly before each treatment begins.

During the infusion, medical staff will monitor you closely for any signs of a reaction. You will also be observed for at least one hour after the infusion is finished to ensure you are stable before leaving the clinic.

Missed Doses

If you miss an appointment for your infusion, contact your doctor immediately to reschedule. It is important to receive the medication as scheduled. Your healthcare provider will adjust your future dosing schedule to maintain the appropriate time interval between treatments.

Question 9

Is Ocrelizumab safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Ocrelizumab may cause harm to an unborn baby. If you are able to become pregnant, your healthcare provider may perform a pregnancy test before you begin treatment to confirm you are not pregnant.

It is important to use effective birth control during treatment and for at least 6 months after your last dose of ocrelizumab. If you become pregnant during this time, you should contact your healthcare provider immediately.

A pregnancy registry exists to monitor the health of individuals who use ocrelizumab during pregnancy and the health of their babies. This information helps researchers understand the drug's impact on pregnancy outcomes.

Infants who were exposed to ocrelizumab while in the womb may have a temporary reduction in B-cells, which are a type of white blood cell that helps the immune system. Because of this, it is necessary to discuss your infant's vaccination schedule with a doctor, as certain live vaccines may need to be delayed until the child's immune system recovers.

Breastfeeding

It is not known if ocrelizumab passes into breast milk or if it could affect a nursing infant. You should talk to your healthcare provider about the risks and benefits of breastfeeding while receiving this medication.

Question 10

What forms and strengths does Ocrelizumab come in?

Accepted Answer

Ocrelizumab is supplied in the following form:

Intravenous Solution: A sterile, preservative-free liquid provided in single-dose vials for infusion into a vein.

The solution is concentrated and must be diluted by a healthcare provider before use. It typically appears clear to slightly opalescent and may be colorless to pale brown.

Question 11

What is the FDA approval status of Ocrelizumab?

Accepted Answer

FDA Approval and Indications

Ocrelizumab is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with relapsing forms of multiple sclerosis (MS), which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is also approved for the treatment of primary progressive multiple sclerosis (PPMS).

Regulatory Safety Communications

The FDA continuously monitors the safety profile of ocrelizumab. In 2020, the FDA investigated a potential safety signal regarding breast cancer based on reports in the FDA Adverse Event Reporting System (FAERS). Following an evaluation of the available data, the FDA concluded that no regulatory action was required at that time.

Prescribing Requirements

The FDA requires specific screening and monitoring for patients prescribed ocrelizumab. Healthcare providers must screen patients for hepatitis B virus (HBV) infection prior to the first dose, as the medication can lead to virus reactivation. Additionally, the drug must be administered in a clinical setting equipped to manage serious infusion-related reactions.

Question 12

What should I know about Ocrelizumab and cost?

Accepted Answer

Factors Influencing Cost

The total cost of ocrelizumab treatment is influenced by several variables. Because it is a biologic medication administered by a healthcare professional, the price includes both the drug itself and the services required to provide the infusion.

Insurance Coverage: Out-of-pocket expenses depend on the specific terms of a health insurance plan, including deductibles and coinsurance rates.

Facility Fees: Costs can vary depending on whether the infusion is received at a hospital, a specialized infusion center, or a doctor's office.

Generic Status: There is currently no generic or biosimilar version of ocrelizumab available. Biologic medications typically maintain higher costs until biosimilar alternatives enter the market.

Financial Assistance

Patients may be able to reduce their out-of-pocket costs through manufacturer-sponsored programs. These may include copay assistance for those with private insurance or support programs for patients who are uninsured or meet specific financial need criteria. It is recommended to consult with a healthcare provider or insurance coordinator to understand specific coverage details and available support.

Ocrelizumab

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?